{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:31:29Z","timestamp":1759602689490},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T00:00:00Z","timestamp":1405555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1245\/s10434-014-3889-x","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T15:47:24Z","timestamp":1405525644000},"page":"743-749","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Significance of GAB2, a Scaffolding\/Docking Protein Acting Downstream of EGFR in Human Colorectal Cancer"],"prefix":"10.1245","volume":"21","author":[{"given":"Tae","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Sugimachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Uchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genta","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenari","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Sakimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ueo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kurashige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Shinden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshi","family":"Mimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,17]]},"reference":[{"key":"3889_CR1","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(12)60919-2","volume":"380","author":"I Soerjomataram","year":"2012","unstructured":"Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380:1840\u201350.","journal-title":"Lancet."},{"key":"3889_CR2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389\u2013400.","journal-title":"Nat Med."},{"key":"3889_CR3","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160\u201374.","journal-title":"N Engl J Med."},{"key":"3889_CR4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0962-8924(03)00002-3","volume":"13","author":"H Gu","year":"2003","unstructured":"Gu H, Neel BG. The \u201cGab\u201d in signal transduction. Trends Cell Biol. 2003;13:122\u201330.","journal-title":"Trends Cell Biol."},{"key":"3889_CR5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1478-811X-7-22","volume":"7","author":"FU Wohrle","year":"2009","unstructured":"Wohrle FU, Daly RJ, Brummer T. Function, regulation and pathological roles of the Gab\/DOS docking proteins. Cell Commun Signal. 2009;7:22.","journal-title":"Cell Commun Signal."},{"key":"3889_CR6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/BJ20050229","volume":"391","author":"S Meng","year":"2005","unstructured":"Meng S, Chen Z, Munoz-Antonia T, Wu J. Participation of both Gab1 and Gab2 in the activation of the ERK\/MAPK pathway by epidermal growth factor. Biochem J. 2005;391:143\u201351.","journal-title":"Biochem J."},{"key":"3889_CR7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1128\/MCB.01353-12","volume":"33","author":"X Zhang","year":"2013","unstructured":"Zhang X, Lavoie G, Fort L, et al. Gab2 phosphorylation by RSK inhibits Shp2 recruitment and cell motility. Mol Cell Biol. 2013;33:1657\u201370.","journal-title":"Mol Cell Biol."},{"key":"3889_CR8","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1158\/0008-5472.CAN-03-3106","volume":"64","author":"JG Jackson","year":"2004","unstructured":"Jackson JG, St Clair P, Sliwkowski MX, et al. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the Anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res. 2004;64:2601\u20139.","journal-title":"Cancer Res."},{"key":"3889_CR9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1541-7786.MCR-12-0352","volume":"10","author":"SJ Adams","year":"2012","unstructured":"Adams SJ, Aydin IT, Celebi JT. GAB2\u2014a scaffolding protein in cancer. Mol Cancer Res. 2012;10:1265\u201370.","journal-title":"Mol Cancer Res."},{"key":"3889_CR10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nm1341","volume":"12","author":"M Bentires-Alj","year":"2006","unstructured":"Bentires-Alj M, Gil SG, Chan R, et al. A role for the scaffolding adapter GAB2 in breast cancer. Nat Med. 2006;12:114\u201321.","journal-title":"Nat Med."},{"key":"3889_CR11","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1038\/onc.2009.296","volume":"28","author":"A Mira","year":"2009","unstructured":"Mira A, Isella C, Renzulli T, et al. The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer. Oncogene. 2009;28:4444\u201355.","journal-title":"Oncogene."},{"key":"3889_CR12","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/ijc.25172","volume":"127","author":"ED Fleuren","year":"2010","unstructured":"Fleuren ED, O\u2019Toole S, Millar EK, et al. Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. Int J Cancer. 2010;127:1486\u201392.","journal-title":"Int J Cancer."},{"key":"3889_CR13","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1038\/onc.2012.367","volume":"32","author":"Y Yang","year":"2013","unstructured":"Yang Y, Wu J, Demir A, et al. GAB2 induces tumor angiogenesis in NRAS-driven melanoma. Oncogene. 2013;32:3627\u201337.","journal-title":"Oncogene."},{"key":"3889_CR14","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/onc.2011.435","volume":"31","author":"Y Wang","year":"2012","unstructured":"Wang Y, Sheng Q, Spillman MA, Behbakht K, et al. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3\u00a0K pathway in ovarian cancer cells. Oncogene. 2012;31:2512\u201320.","journal-title":"Oncogene."},{"key":"3889_CR15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.7150\/ijbs.7.496","volume":"7","author":"XL Xu","year":"2011","unstructured":"Xu XL, Wang X, Chen ZL, et al. Overexpression of Grb2-associated binder 2 in human lung cancer. Int J Biol Sci. 2011;7:496\u2013504.","journal-title":"Int J Biol Sci."},{"key":"3889_CR16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/onc.2009.364","volume":"29","author":"M Bocanegra","year":"2010","unstructured":"Bocanegra M, Bergamaschi A, Kim YH, et al. Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene. 2010;29:774\u20139.","journal-title":"Oncogene."},{"key":"3889_CR17","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2353\/ajpath.2009.080543","volume":"174","author":"B Horst","year":"2009","unstructured":"Horst B, Gruvberger-Saal SK, Hopkins BD, et al. Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol. 2009;174:1524\u201333.","journal-title":"Am J Pathol."},{"key":"3889_CR18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/gcc.20344","volume":"45","author":"A Zatkova","year":"2006","unstructured":"Zatkova A, Schoch C, Speleman F, et al. GAB2 is a novel target of 11q amplification in AML\/MDS. Gene Chromosome Cancer. 2006;45:798\u2013807.","journal-title":"Gene Chromosome Cancer."},{"key":"3889_CR19","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/1078-0432.CCR-09-0280","volume":"15","author":"KA Chernoff","year":"2009","unstructured":"Chernoff KA, Bordone L, Horst B, et al. GAB2 Amplifications refine molecular classification of melanoma. Clin Cancer Res. 2009;15:4288\u201391.","journal-title":"Clin Cancer Res."},{"key":"3889_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1091\/mbc.E10-03-0185","volume":"22","author":"MT Herrera Abreu","year":"2011","unstructured":"Herrera Abreu MT, Hughes WE, Mele K, et al. Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation. Mol Biol Cell. 2011;22:105\u201316.","journal-title":"Mol Biol Cell."},{"key":"3889_CR21","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1038\/sj.onc.1210315","volume":"26","author":"Y Ke","year":"2007","unstructured":"Ke Y, Wu D, Princen F, et al. Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene. 2007;26:4951\u201360.","journal-title":"Oncogene."},{"key":"3889_CR22","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1158\/1078-0432.CCR-09-1431","volume":"15","author":"RN Jorissen","year":"2009","unstructured":"Jorissen RN, Gibbs P, Christie M, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res. 2009;15:7642\u201351.","journal-title":"Clin Cancer Res."},{"key":"3889_CR23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","volume":"439","author":"AH Bild","year":"2006","unstructured":"Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353\u20137.","journal-title":"Nature."},{"key":"3889_CR24","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"3889_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alternation in human cancers. Genome Biol. 2011;12:41.","journal-title":"Genome Biol."},{"issue":"268","key":"3889_CR26","doi-asserted-by":"crossref","first-page":"pe10","DOI":"10.1126\/scisignal.2004021","volume":"6","author":"WG Cance","year":"2013","unstructured":"Cance WG, Kurenova E, Marlowe T, et al. Disrupting the scaffold to improve focal adhesion kinase targeted cancer therapeutics. Sci Signal. 2013;6(268):pe10.","journal-title":"Sci Signal."},{"key":"3889_CR27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.humpath.2012.05.005","volume":"44","author":"A Azusa","year":"2013","unstructured":"Azusa A, Takeo M, Hiroyuki O, et al. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum Pathol. 2013;44:199\u2013207.","journal-title":"Hum Pathol."},{"key":"3889_CR28","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/ijc.21461","volume":"118","author":"BI Bertelsen","year":"2006","unstructured":"Bertelsen BI, Steine SJ, Sandvei R, et al. Molecular analysis of the PI3\u00a0K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer. 2006;118:1877\u201383.","journal-title":"Int J Cancer."},{"key":"3889_CR29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","volume":"17","author":"F Chan","year":"2003","unstructured":"Chan F, Lee JT, Navolanic PM, et al. Involvement of PI3\u00a0K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590\u2013603.","journal-title":"Leukemia."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-014-3889-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3889-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T22:09:35Z","timestamp":1565647775000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-014-3889-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,17]]},"references-count":29,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3889"],"URL":"https:\/\/doi.org\/10.1245\/s10434-014-3889-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,17]]}}}